Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Nuclear Medicine, PET, and Radiopharmaceuticals Market Size, Trends and Forecast 2025-2036 | Theranostics, Digital PET, and AI Unlock High-Growth Opportunities

globenewswire.com
GEHC GE HealthCare is mentioned as an integrated molecular-imaging OEM and software platform in the nuclear medicine market, a sector expected to grow with advancements in theranostics and AI. LLY Eli Lilly, through its acquisition of POINT Biopharma, is positioned as a therapeutic radiopharma and theranostics developer in the expanding nuclear medicine market. BMY Bristol Myers Squibb, via its acquisition of RayzeBio, is noted as a therapeutic radiopharma and theranostics developer in the nuclear medicine sector poised for growth. AZN AstraZeneca, through its acquisition of Fusion Pharmaceuticals, is recognized as a therapeutic radiopharma and theranostics developer in the nuclear medicine market. CBZ Cardinal Health is mentioned as a company involved in the distribution infrastructure for the nuclear medicine market, which is expected to grow with theranostics and AI. BWXT BWX Technologies is listed as a company involved in isotope supply for the nuclear medicine market, which is projected to expand with theranostics and AI.

Global Nuclear Medicine, PET, and Radiopharmaceuticals Market Size, Trends and Forecast 2025-2036 | Theranostics, Digital PET, and AI Unlock High-Growth Opportunities Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Global Nuclear Medicine & PET Market Horizon: Market Structure, Forecasts, Competitive Dynamics, Theranostics, and AI / Workflow Monetization, 2025A-2036E" has been added to ResearchAndMarkets.com's offering.

The report delivers an integrated global analysis of the Nuclear Medicine market, including PET, SPECT, radiopharmaceuticals, theranostics, medical isotopes, software, manufacturing, distribution, and provider capacity. Designed for molecular-imaging OEMs, radiopharmaceutical companies, isotope suppliers, nuclear-pharmacy organizations, healthcare providers, investors, and corporate strategy teams, it identifies where value is expected to accumulate as the industry evolves beyond scanner-centered business models.

A reconciled market model connects equipment systems, active installed bases, replacement and expansion shipments, realized ASPs, service revenue, diagnostic radiopharmaceuticals, therapeutic products, isotope availability, reimbursement, provider capacity, AI, dosimetry, and workflow software. Base, Bull, and Bear scenarios quantify market development from 2025A through 2036E while separating clinical potential from achievable commercial revenue.

The analysis was developed through Markintel, the analyst's proprietary research methodology and strategic framework stack. It combines bottom-up market modeling with regulatory, clinical, reimbursement, procurement, manufacturing, company, and provider-operating evidence.

Nuclear Medicine Market Outlook

Nuclear Medicine is transitioning into an integrated diagnostic and therapeutic ecosystem. Radiopharmaceuticals represent most market value and growth, with diagnostics remaining the largest revenue segment and therapeutic radiopharmaceuticals becoming the primary expansion engine. Equipment continues to provide the essential access platform, supported by growing demand for digital PET/CT, long-axial-field-of-view PET, PET/MR, SPECT/CT, software upgrades, and lifecycle services.

Established Tc-99m and FDG pathways retain significant scale, while PSMA, cardiac, neuro, and specialty PET create incremental product and workflow opportunities. Radioligand therapy offers substantial commercial potential, but market realization depends on isotope supply, product-specific manufacturing, distribution, reimbursement, licensed personnel, treatment rooms, scheduling, and completion of prescribed treatment courses.

North America remains the largest commercial market, while Europe maintains an extensive clinical and installed base. China, India, and other Asia-Pacific markets gain share through equipment expansion, local radiopharmaceutical production, public procurement, private oncology investment, and provider-network development.

Key Market Trends and Growth Drivers

Competitive Landscape

The report organizes the Nuclear Medicine competitive landscape into eight strategic clusters: integrated molecular-imaging OEMs and software platforms; diagnostic radiopharmaceutical companies; therapeutic radiopharma and theranostics developers; isotope, generator, CDMO, and distribution infrastructure; quantification, dosimetry, and image-enhancement specialists; enterprise workflow and reporting platforms; provider networks and theranostics centers; and life-sciences, trial-imaging, and radiopharma-QC software providers.

Competitive analysis addresses revenue exposure, commercial control, product maturity, installed-base advantages, distribution capabilities, isotope dependencies, provider access, geographic positioning, execution risks, and partnership or acquisition potential. Equipment share, diagnostic product share, therapeutic product share, isotope control, software adoption, and provider access are evaluated independently.

Companies covered include GE HealthCare, Siemens Healthineers, United Imaging Healthcare, Philips, Mediso, Spectrum Dynamics Medical, Lantheus, Telix Pharmaceuticals, Novartis, Eli Lilly / POINT Biopharma, Bristol Myers Squibb / RayzeBio, AstraZeneca / Fusion Pharmaceuticals, ITM / Lumara Bio, Clarity Pharmaceuticals, Perspective Therapeutics, Curium, Bracco / Blue Earth Diagnostics, Jubilant Pharmova, Cardinal Health, Eckert & Ziegler, SHINE Technologies, Nucleus RadioPharma, BWX Technologies, NorthStar Medical Radioisotopes, TerraPower Isotopes, Nusano, AdvanCell, Hermes Medical Solutions, Subtle Medical, AIQ Solutions, Sectra, Visage Imaging / Pro Medicus, LabLogic, and Elysia-Raytest.

Report Coverage

The market model covers equipment, installed-base development, replacement cycles, expansion shipments, realized ASPs, service, and lifecycle value. Radiopharmaceutical analysis includes Tc-99m products, FDG, PSMA PET, SSTR imaging, cardiac PET tracers, amyloid, tau, specialty PET, commercial radioligand therapies, and late-stage therapeutic programs involving Lu-177, Ac-225, Pb-212, Cu-67, Y-90, and I-131 strategies.

Geographic coverage includes North America, Europe, China, Japan and South Korea, India, Rest of Asia-Pacific, Latin America, and the Middle East and Africa. Country-level analysis assesses registration, reimbursement, local production, distribution, service infrastructure, workforce availability, and provider readiness.

The report supports market-entry planning, regional prioritization, competitor benchmarking, partnership and acquisition assessment, adjacent-market sizing, investment analysis, and Nuclear Medicine forecasting. It is intended for organizations seeking to identify strategic bottlenecks, evaluate commercial readiness, and determine which technologies, companies, and regions are positioned to capture value through 2036E.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/6g6w1e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.